Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05546580 | RECRUITING | Acute Myeloid Leukemia, in Relapse

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Sponsor:

Oryzon Genomics S.A.

Brief Summary:

Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML.

Condition or disease

Acute Myeloid Leukemia, in Relapse

Acute Myeloid Leukemia Refractory

Intervention/treatment

Iadademstat

Gilteritinib Oral Tablet

Phase

PHASE1

Detailed Description:

This is an escalation/expansion, open label, single arm, study to investigate the safety and the RP2D of the combination of iadademstat with gilteritinib in FLT3-mutated R/R AML. This study consists of 2 parts. A dose finding part to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and emerging activity of iadademstat and gilteritinib combination, and to determine the pharmacologically-active dose (i.e., the minimum safe and biologically active dose) of iadademstat in combination with gilteritinib, and an expansion part at the specific dose/s selected to evaluate the activity of iadademstat in combination with gilteritinib in patients with FLT3-mutated R/R AML.

Study Type : INTERVENTIONAL
Estimated Enrollment : 50 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+): The FRIDA Study
Actual Study Start Date : 2022-11-14
Estimated Primary Completion Date : 2025-11-30
Estimated Study Completion Date : 2025-11-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Main Inclusion Criteria
  • * Diagnosis of primary AML or AML with myelodysplasia-related changes (AML-MRC)
  • * Patient is in first or second relapse or has refractory disease. Patients must have had histologic verification of AML at the original diagnosis.
  • * Patient must be positive for the following FLT3 mutations in bone marrow or PB: FLT3 internal tandem duplication (ITD), FLT3 tyrosine kinase domain (TKD) D835 or I836 or FLT3-ITD and specified FLT3-TKD.
  • * ECOG performance status 0-2
  • * Life expectancy of at least 3 months in the opinion of the investigator.
  • * Normal hepatic and renal function.
  • * Patient is able to swallow oral medications.
  • * Female patients are postmenopausal, documented as surgically sterile, use two methods of contraception or practice true abstinence and have a negative urine pregnancy test at screening.
  • * Male patients even if surgically sterilized agree to practice true abstinence or use highly effective barrier contraception.
  • Main Exclusion Criteria
    • * Diagnosis of acute promyelocytic leukemia.
    • * Known BCR-ABL-positive leukemia.
    • * AML secondary to prior chemotherapy for other neoplasms (except for MDS).
    • * AML that has relapsed after or is refractory to more than 2 lines of therapy.
    • * Clinically active central nervous system leukemia or prior history of NCI CTCAE Grade ≥ 3 drug-related CNS toxicity.
    • * Major surgery or radiation therapy within 4 weeks prior to the first study dose.
    • * Prior treatment with iadademstat is not allowed. Treatment with any other agents with KDM1A/LSD1 inhibitory activity is only allowed if treatment finalized at least 3 weeks prior to first dose on study. Previous treatment with FLT3 inhibitors is allowed in the following cases: midostaurin and sorafenib are allowed when used in first-line therapy regimen as part of induction, consolidation and/or maintenance: quizartinib and gilteritinib are allowed when used in first-line therapy regimen, as part of induction, consolidation and/or maintenance, ONLY if patients were not refractory to the drugs or if responding, relapse did not occur while on these drugs.
    • * Patients not eligible to receive gilteritinib per label.
    • * Prior treatment with 3 or more lines of AML therapy.
    • * Treatment with any investigational products within 3 weeks prior to first dose of study treatment.
    • * Uncontrolled hypertension or poorly controlled diabetes.
    • * Evidence of active uncontrolled viral, bacterial, or systemic fungal infection.
    • * Pregnant or lactating women.
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Location Details

NCT05546580

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Arizona

Banner MD Anderson Cancer Center

Gilbert, Arizona, United States, 85234

RECRUITING

United States, Arizona

The University of Arizona Cancer Center - North Campus

Tucson, Arizona, United States, 85724-5024

RECRUITING

United States, Florida

Sylvester Comprehensive Cancer Center

Miami, Florida, United States, 33136

RECRUITING

United States, Florida

Miami Cancer Institute

Miami, Florida, United States, 33176

RECRUITING

United States, Maryland

The John Hopkins University School of Medicine

Baltimore, Maryland, United States, 21287-0013

RECRUITING

United States, Massachusetts

Massachusetts General Hospital (MGH)

Boston, Massachusetts, United States, 02114

RECRUITING

United States, New Jersey

Rutgers, The State University

Piscataway, New Jersey, United States, 08854

RECRUITING

United States, New York

Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital

New York, New York, United States, 10029

RECRUITING

United States, North Carolina

Duke University Medical Center

Durham, North Carolina, United States, 27705

RECRUITING

United States, Oregon

Oregon Health & Science University

Portland, Oregon, United States, 97239

RECRUITING

United States, Tennessee

Sarah Cannon Research Institute, LLC

Nashville, Tennessee, United States, 37203

RECRUITING

United States, West Virginia

West Virginia University

Morgantown, West Virginia, United States, 26506

RECRUITING

United States, Wisconsin

Froedtert Hospital & The Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53226